Metastat Inc · OTC:MTST
Metastat — Investor Presentation (December 2015)
23 slides from Metastat's investor presentation, Dec 4, 2015
Slide 1: MetaStat Corporate Presentation Fall 2015
MetaStat t, I MetaStat, Inc. CORPORATE PRESENTATION Fall2015
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS presentation contains forwardlocking statements within the meaning ofthe Secures Act of1933, as amended, theSecutes Eon a8 sande andthe Prt Sc gtr Rr cf 85 witha nee obec by tee ‘youcan rward-eoking statements by wor s the growthof the markets aderessed by our products the
Slide 3: MetaStat, Inc. (OTCQB: MTST)
METASTAT, INC. (OTCQB: MTST) UNIQUE BIOLOGY-DRIVEN, ACTIONABLE TI treatment decision: + MetaSite Breast™ 4 + MenaCalc™ 1,700 patients 1) MA
Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS com @ Bim B Mit GD ance’ Fa pawrnen bane
Slide 5: Leadership Team
LEADERSHIP TEAM F Douglas Hamilton BSc. MBA - Presidentand CEO eee + Forme CO0andcrOatiovenPhamacutials + Amgen, Pier, PolaRx, GE Lifesciences and New BiologyVentures Michael Donovan M.D., Ph.D. - Acting Chief Medical Officer + Professor at leahn School of Medicine at Mt Sinai + Millennium, cyte and
Slide 6: Advisory Board Members
ADVISORY BOARD MEMBERS SCIENTIFIC & CLINICAL ADVISORY BOA\ Oscar Bronsther, M.D. - Chain + fal ate Suey, ere Wasting Unesy ‘Sectn of General Surgery nova Fairfax Hospital John S. Condeclis, + Abert en me oie Teh ron P Resnick Coen Tranoal Research or ance of Aeatony andl Bay acai o) tse te of Tecay
Slide 7: Challenges Facing Practicing Oncologists
CHALLENGES FACING PRACTICING ONCOLOGISTS WHAT IS THE OPTIMAL THERAPY AND IS ADJUVANT CHEMOTHERAPY WARRANTED? Only However, a majority, Co) Co) ~30-35% ~70-80% of early stage newly diagnosed invasive of early stage newly diagnosed invasive breast cancer breast cancer patient: IS AGGRESSIVE AND ARE re
Slide 8: MetaStat Providing the Answers
METASTAT PROVIDING THE ANSWERS OUR TESTS PROVIDE ONCOLOGISTS WITH ACTIONABLE INFORMATION TO INFLUENCE TREATMENT DECISIONS Chemotherapeutic Benefit + HIGH-RISK Patients + LOW-RISK Patients i Treatment Strategies
Slide 9: Mena Drives Metastasis Process
MENA'XY DRIVES PROCESS * Isoforms have functionally-distinct activity a + Promotes invasion and motility of tumor cells, ° G + Jes Increases sensitivity 0 vascular chemoattract sitivi -moattractai aa + Regulator of RTK signaling, drives sensitivity to growth factors, and resistance to targeted inhib
Slide 10: The MetaSite Breast Test
THE METASITE BREAST ™ TEST PATENTED IHC TISSUE-B METASTASIS FOR ER+, HER2. + Portal for entry of tumor cellsto circulation MS aNAaS Low-Risk patient
Slide 11: The MenaCalc Platform
THE MENACALC™ PLATFORM. A PATENTED QIF TISSUE-BASED TEST TE INVASIVENESS AND I: E PROSTATE, CRC) of the cancer spreading High MenaCalc™ Score Low MenaCalc™ Score ‘YELLOW Pan Mena RED Menait® High-Risk patient Low-Risk patient -@
Slide 12: Breast Journey
BREAST JOURNEY have been diagnosed I have had local therapy wen sage HM breast | urgery ander mlaton) ‘eancer, ton rand hormone Dole aa tumor cells, but what next? > Adjuvant ‘Chemotherapy? HIGH RISK = CHEMO LOW Risk = NO CHEMO Is chemo really necessary? Can avoid the sickness, pain and hair loss as
Slide 13: Value Proposition
VALUE PROPOSITION ACTIONABLE TEST RESULTS TO ALLOW ONCOLOGISTS TO PERSONALIZE TREATMENT STRATEGIES INCLUDING PROVIDERS actionable information to key clinical questions : “ Demonstrates the merits of treatment with adjuvant chemotherapy No additional tests or procedures + Fits into current clinical w
Slide 14: Successful Clinical Studies in Over 1,700 Breast Cancer Patients
SUCCESSFUL CLINICAL STUDIES 5 SUCCESSFUL STUDIES IN OVER 1,700 BREAST CANCER PATIENTS MetaSite Breast" Prognostic for all molecular subtypes of breast cancer ~ Sper biedinHca Caner Resch biota 2009 + MetaSte density prediedthe development metasassandindependettof clinical pognostators MenaCalc™ Brea
Slide 15: Clinical Study Plan
CLINICAL STUDY PLAN CLINICAL STUDIES TO SUPPORT COMMERCIAL LAUNCH Prognostic cor - ‘valine data QY'16 + Define the product specifications and risk Breast™ score (Kaiser A) and’ or MenaCale™ score + Primary endpoint ~ direct association betw triple negative TN) and/or HER2+ invasive breast cancer pop
Slide 16: Market Opportunity
MARKET OPPORTUNIT' EAST CANCER DIAGNOSTIC: UP TO 84% oF ALL PATIENTS DO NOT HAVE EITHER AN APPLICABLE DIAGNOSTIC TEST NOR AN Kenna LE ONE 1. Unmet Medical Need Segment = 1s Gueeeinanit ames ING Hea) 40% 0F 74,000 p: 2. Under-penetrated Segment + Dx tests available but not used (cost, evidence) + -24
Slide 17: Competitive Landscape
COMPETITIVE LANDSCAPE Metasite Breast™ MenaCalc™ Oncotype DX® ‘MammaPrint® Prosigna® ied MetaStat Metastat Genomic ‘Health Agendia Nanostring Novartis (Genoptix) Met density Pan Mena — ‘Mena 21 gene panel 70 gene panel 50 gene panel ER PR Her, Ki67 Triple Ic uantitative immuno- fluorescence Platform
Slide 18: Large U.S. Market Potential
LARGE U.S. MARKET POTENTIAL INITIAL $231 MILLION ANNUAL ADDRESSABLE U MILLION (S™ YEAR SALES MODEL) sam Indication Indication Indication tn
Slide 19: Compelling Business Model
COMPELLING BUSINESS MODEL of +11.8%) codes ~$3 million to perform clinical studies per indication
Slide 20: Strong IP Position
STRONG IP POSITION Broad Intellectual Property Position Patents filed .S. patents and 1 European patent issued and discover Ea iest expiration for core technology is 2030 Freedom to Operate Using our Novel Technology Morgan, Lewis, and Bockius, LLP ~ Company counsel + Amster, Rothstein, and Ebenstei
Slide 21: Key Milestones
KEY MILESTONES ‘Assay Method Development and Analytical Validation MetaSite Breast™ MenaCale™ Breast and Certification Clinical Development Program Key Peer-review Data Presentation CLIA laboratory certification from CMS Prognostic MetaSte Breast™ replication stud (ike A oe | Prognostic MetaSte Brea
Slide 22: Superior Diagnostics with Actionable Information
SUPERIOR DIANOSTICS WITH ACTIONABLE INFORMATION TO: * Personalize treatment strategies for the individual cancer pat + Wend . Snspicelercad jonse to chemot! + Progroste for and predict of response to taxanedbaed therapy + Prognostic for and predictive of resistance to targeted RTK inhibitors + LDT s
Slide 23: Key Statistics
KEY STATISTICS KEY STATISTICS TCQB: MTST) Ticker Symbol: (OTCQB: ‘Common Shares: 1,851,201 Fully Diluted Shares: 3,559,523 Market Cap (12/2/15): $10.2 million Debt: $1.2 million # Employees: 5 Full Time; 5 Part Time Boston, MA Location: